Azathioprine-induced severe cholestatic hepatitis in patient carrying TPMT*3C polymorphism
- PMID: 20972624
- DOI: 10.1007/s11096-010-9443-4
Azathioprine-induced severe cholestatic hepatitis in patient carrying TPMT*3C polymorphism
Abstract
Case description: A 40-year-old man with pemphigus foliaceus developed a jaundice and pruritus three weeks after starting azathioprine 100 mg daily. Laboratory investigations revealed a severe cholestatic hepatitis. Azathioprine-induced hepatitis was suspected. The dosage of thiopurine methyltransferase activity showed a low activity of the enzyme and the genotype of this enzyme found a TPMT*3C heterozygous mutant allele. Azathioprine was withdrawn. The icterus regressed progressively and the hepatic tests normalised slowly. The patient had no further episodes of hepatitis over a follow-up period of 6 months.
Conclusion: Although, hematotoxicity seems to be associated with homozygous TPMT variants, a possible association between azathioprine hepatotoxicity and a TPMT*3C genotype should be investigated further.
Similar articles
-
Impact of the heterozygous TPMT*1/*3C genotype on azathioprine-induced myelosuppression in kidney transplant recipients in Thailand.Clin Ther. 2009 Jul;31(7):1524-33. doi: 10.1016/j.clinthera.2009.07.008. Clin Ther. 2009. PMID: 19695401
-
Azathioprine-induced fatal myelosuppression in systemic lupus erythematosus patient carrying TPMT*3C polymorphism.Lupus. 2008 Feb;17(2):132-4. doi: 10.1177/0961203307085255. Lupus. 2008. PMID: 18250137
-
Thiopurine S-methyltransferase gene polymorphism in Japanese patients with autoimmune liver diseases.Liver Int. 2007 Feb;27(1):95-100. doi: 10.1111/j.1478-3231.2006.01392.x. Liver Int. 2007. PMID: 17241387
-
Clinical pharmacogenomics of thiopurine S-methyltransferase.Curr Clin Pharmacol. 2006 Jan;1(1):119-28. doi: 10.2174/157488406784111627. Curr Clin Pharmacol. 2006. PMID: 18666383 Review.
-
Relevance of thiopurine methyltransferase status in rheumatology patients receiving azathioprine.Rheumatology (Oxford). 2004 Jan;43(1):13-8. doi: 10.1093/rheumatology/keg442. Epub 2003 Oct 17. Rheumatology (Oxford). 2004. PMID: 14566029 Review.
Cited by
-
Azathioprine induced hepatitis in patients with inflammatory bowel disease.Int J Clin Pharm. 2011 Oct;33(5):724-5. doi: 10.1007/s11096-011-9557-3. Epub 2011 Sep 3. Int J Clin Pharm. 2011. PMID: 21892694 No abstract available.
-
Severe cholestasis due to azathioprine in Behcet's disease.BMJ Case Rep. 2019 Mar 31;12(3):e226340. doi: 10.1136/bcr-2018-226340. BMJ Case Rep. 2019. PMID: 30936327 Free PMC article.
-
Severe azathioprine-induced liver injury 22 months after initiation of treatment.BMJ Case Rep. 2022 Dec 21;15(12):e253505. doi: 10.1136/bcr-2022-253505. BMJ Case Rep. 2022. PMID: 36543371 Free PMC article.
-
Azathioprine-induced hepatitis and cholestasis occurring 1 year after treatment.BMJ Case Rep. 2014 Dec 3;2014:bcr2014206859. doi: 10.1136/bcr-2014-206859. BMJ Case Rep. 2014. PMID: 25471111 Free PMC article. Review.
-
High prevalence of cholestasis, with increased conjugated bile acids in inflammatory bowel diseases patients.World J Clin Cases. 2018 Apr 16;6(4):44-53. doi: 10.12998/wjcc.v6.i4.44. World J Clin Cases. 2018. PMID: 29670889 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources